Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
BMC Microbiology 2020-May

In vitro synergistic potentials of novel antibacterial combination therapies against Salmonella enterica serovar Typhimurium.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
O link é salvo na área de transferência
Md Hossain
Hae-Chul Park
Kwang-Jick Lee
Sung-Won Park
Seung-Chun Park
JeongWoo Kang

Palavras-chave

Resumo

The antibiotics generally used in farm animals are rapidly losing their effectiveness all over the world as bacteria develop antibiotic resistance. Like some other pathogenic bacteria multidrug-resistant strains of Salmonella enterica serovar Typhimurium (S. Typhimurium) are also frequently found in animals and humans which poses a major public health concern. New strategies are needed to block the development of resistance and to prolong the life of traditional antibiotics. Thus, this study aimed to increase the efficacy of existing antibiotics against S. Typhimurium by combining them with opportunistic phenolic compounds gallic acid (GA), epicatechin, epicatechin gallate, epigallocatechin and hamamelitannin. Fractional inhibitory concentration indexes (FICI) of phenolic compound-antibiotic combinations against S. Typhimurium were determined. Based on the FICI and clinical importance, 1 combination (GA and ceftiofur) was selected for evaluating its effects on the virulence factors of this bacterium. Viability of Rattus norvegicus (IEC-6) cell in presence of this antibacterial combination was evaluated.Minimum inhibitory concentrations (MICs) of GA, epigallocatechin and hamamelitannin found against different strains of S. Typhimurium were 256, (512-1024), and (512-1024) μg/mL, respectively. Synergistic antibacterial effect was obtained from the combination of erythromycin-epicatechin gallate (FICI: 0.50) against S. Typhimurium. Moreover, additive effects (FICI: 0.502-0.750) were obtained from 16 combinations against this bacterium. The time-kill assay and ultrastructural morphology showed that GA-ceftiofur combination more efficiently inhibited the growth of S. Typhimurium compared to individual antimicrobials. Biofilm viability, and swimming and swarming motilities of S. Typhimurium in presence of GA-ceftiofur combination were more competently inhibited than individual antimicrobials. Viabilities of IEC-6 cells were more significantly enhanced by GA-ceftiofur combinations than these antibacterials alone.This study suggests that GA-ceftiofur combination can be potential medication to treat S. Typhimurium-associated diarrhea and prevent S. Typhimurium-associated blood-stream infections (e.g.: fever) in farm animals, and ultimately its transmission from animal to human. Further in vivo study to confirm these effects and safety profiles in farm animal should be undertaken for establishing these combinations as medications.

Junte-se à nossa
página do facebook

O mais completo banco de dados de ervas medicinais apoiado pela ciência

  • Funciona em 55 idiomas
  • Curas herbais apoiadas pela ciência
  • Reconhecimento de ervas por imagem
  • Mapa GPS interativo - marcar ervas no local (em breve)
  • Leia publicações científicas relacionadas à sua pesquisa
  • Pesquise ervas medicinais por seus efeitos
  • Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas

Google Play badgeApp Store badge